STOCK TITAN

Atossa Therapeutics Inc - ATOS STOCK NEWS

Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.

Overview

Atossa Therapeutics Inc (ATOS) is a clinical stage biopharmaceutical company that develops and markets innovative medicines, laboratory tests, and therapeutic delivery platforms focused on addressing unmet medical needs in oncology. With a primary emphasis on women’s breast health and breast cancer, the company is dedicated to advancing novel drug candidates and precision-targeted delivery systems, employing cutting-edge approaches such as selective estrogen receptor modulation and intraductal microcatheter technology.

Core Therapeutic Focus

The company’s flagship asset, (Z)-endoxifen, exemplifies its commitment to tackling critical challenges in breast cancer treatment. (Z)-endoxifen is a potent selective estrogen receptor modulator (SERM) that not only inhibits estrogen receptor activity but also facilitates its degradation. This dual action is strategically designed to address cases where resistance to traditional hormonal therapies exists, thus filling a significant therapeutic gap in oncology. Additionally, the formulation of (Z)-endoxifen is developed as an oral medication that bypasses the liver metabolism and gastric degradation issues, ensuring optimal bioavailability at therapeutic concentrations.

Innovative Drug Delivery Platforms

Beyond its core drug candidates, Atossa Therapeutics is also pioneering advanced delivery mechanisms to enhance therapeutic efficacy. The development of intraductal microcatheter technology represents a novel approach to deliver therapies directly to the site of breast cancer, thereby improving the targeting of treatments such as hormonal therapies, immunotherapies, and chimeric antigen receptor T-cell therapies. This targeted delivery strategy not only heightens the precision of treatment but also has the potential to reduce systemic side effects, contributing to an overall improved patient experience.

Clinical Development and Research Programs

Atossa’s development pipeline is robust, with multiple Phase 2 trials designed to evaluate the effectiveness of (Z)-endoxifen in diverse patient populations, including women with measurable breast density and those diagnosed with ductal carcinoma in situ. The company’s research initiatives extend to combination therapies, where (Z)-endoxifen is studied alongside other agents such as cyclin-dependent kinase (CDK) inhibitors, further broadening the therapeutic paradigm in breast cancer treatment. These programs underscore the company’s strategic emphasis on targeted oncology, employing rigorous clinical methods to substantiate the efficacy and safety of its novel therapies.

Intellectual Property and Market Position

Central to Atossa’s strategy is its strong intellectual property portfolio, which includes multiple issued U.S. patents and numerous pending applications. These patents cover both the composition of matter for (Z)-endoxifen and innovative formulation approaches, ensuring a competitive edge in the market. By protecting its technology and research investments, the company lays a solid foundation for long-term value creation, even as it navigates the challenges inherent to clinical stage development.

Competitive Landscape and Industry Expertise

Operating within the highly competitive biopharmaceutical industry, Atossa Therapeutics distinguishes itself through its integrated approach to drug development and delivery innovation. Its expertise in designing treatments that address both the efficacy and tolerability aspects of cancer care positions it uniquely among its peers. The company’s focus on precise molecular targeting and the development of therapeutics that are supported by robust scientific data bolsters its role as a knowledgeable and expertly positioned player in the oncology landscape.

Business Model and Operational Strategy

  • Clinical Innovation: Concentrates on advancing clinical programs with a focus on unmet needs in breast cancer and breast health conditions.
  • Targeted Delivery: Emphasizes pioneering approaches in delivering therapies directly to disease sites, using technologies like intraductal microcatheter systems.
  • Intellectual Property: Leverages a strong portfolio of patents to secure its technological advancements and maintain market differentiation.
  • Collaborative Research: Engages in strategic partnerships and clinical collaborations to enhance its research capabilities and validate its clinical hypotheses.

Conclusion

Atossa Therapeutics Inc exemplifies a focused, research-driven approach to addressing significant challenges in oncology. By combining novel therapeutic agents with innovative delivery systems, the company provides a comprehensive model for advancing personalized breast cancer treatment. Its commitment to enhancing patient outcomes through scientific rigor and technological innovation underscores its importance in the dynamic field of biopharmaceutical research. The detailed clinical programs, strategic intellectual property protections, and collaborative research efforts are all testaments to its expertise and nuanced understanding of complex oncology treatment paradigms.

Rhea-AI Summary

Physician-Scientist Dr. Steven C. Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), has been invited to brief U.S. Congress on his research concerning the origins of COVID-19. The virtual meeting will occur on May 24, 2021, where Dr. Quay will discuss evidence supporting the theory of a laboratory-origin virus from Wuhan, China. He contends existing data indicates a lab-leak scenario rather than natural zoonosis. The briefing aims to inform congressional members about these findings, which could influence future safety measures against pandemics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
covid-19
-
Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) reported its Q1 2021 financial results, revealing no sustainable revenue and cash reserves of approximately $137.7 million. The company concluded a Phase 2 study for oral Endoxifen, which showed positive results, and received FDA clearance for expanded access treatment in an ovarian cancer patient. Operating expenses increased by 20% to $3.5 million, driven by a 47% rise in R&D costs. The company plans to expand clinical studies and explore new opportunities moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.88%
Tags
-
Rhea-AI Summary

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced its participation in the Investor Summit Conference on May 18, 2021. CEO Dr. Steven Quay and CFO Kyle Guse will present at 8:45 am ET. The company focuses on developing innovative medicines for unmet medical needs, particularly in oncology and infectious diseases, including breast cancer and COVID-19. Investors can request one-on-one meetings with management after the presentation. For more details, visit Atossa's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.88%
Tags
conferences
Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) urges stockholders to participate in voting for proposals in its proxy statement ahead of the annual stockholder meeting on May 14, 2021. As of March 24, 2021, approximately 17.3 million shares are under lock-up and voting agreements. The company focuses on developing innovative treatments for unmet medical needs in oncology and infectious diseases, particularly breast cancer and COVID-19. For more information on voting and proposals, stockholders can refer to the proxy statement linked in the announcement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
none
-
Rhea-AI Summary

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical firm, announced participation by CEO Dr. Steven Quay in a panel discussion at Cello Health's Cancer Progress Virtual Conference on May 6, 2021, at 10:00 AM ET. The panel, titled 'Investing in the Emerald City of Oncology Innovation,' will include experts from various venture investment funds. Atossa focuses on developing innovative treatments for oncology and infectious diseases, particularly breast cancer and COVID-19. For registration, visit their official site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) announces an ovarian cancer patient has started treatment with its proprietary oral Endoxifen, following FDA approval via the expanded access pathway. This patient, treated by Dr. Barbara Goff at the University of Washington, previously did not tolerate tamoxifen. Molecular testing indicated that Endoxifen combined with alpelisib yielded a significant tumor response. The FDA's expanded access allows use solely for this patient, and Atossa is considering additional clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
none
Rhea-AI Summary

Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported its 2020 financial results, highlighting significant advancements in its clinical programs, particularly for Endoxifen and AT-301. The company concluded a Phase 2 study for Endoxifen early due to positive interim results, accelerated its development plans, and received FDA approval for expanded access in ovarian cancer treatment. Operating expenses declined 15% to approximately $14.6 million, with R&D expenses slightly decreasing. At year-end, Atossa held about $39.7 million in cash, positioning itself well for future opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
-
Rhea-AI Summary

On March 30, 2021, Dr. Steven Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), published an Open Letter addressing the WHO report, emphasizing evidence supporting the lab origin of COVID-19. The letter outlines five undisputed facts indicating the likelihood of a laboratory-acquired infection. Dr. Quay calls for recognition of these facts to prevent future pandemics. He has shared the letter with over thirty global scientists, including WHO investigators, and advocates for a moratorium on gain-of-function research to avoid similar crises.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) announced a registered direct offering of $50 million in common stock and warrants priced at $2.88 per share. The agreement involves the sale of 17,361,100 shares and unregistered warrants for an additional 13,020,825 shares with a four-and-a-half-year expiration period. The offering, expected to close on March 24, 2021, is facilitated by Maxim Group LLC. Proceeds will support the company's clinical-stage operations focusing on oncology and infectious diseases. This move may impact shareholder equity through potential dilution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.07%
Tags
Rhea-AI Summary

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that the FDA issued a "Safe to Proceed" letter allowing the use of their oral Endoxifen as a treatment for a patient with recurrent ovarian cancer. The treatment is being conducted at the University of Washington Medical Center by Dr. Barbara Goff. The patient's tumor responded well to a combination of Endoxifen and alpelisib, prompting Atossa to consider further clinical studies if successful.

Endoxifen, an active metabolite of tamoxifen, has shown significant efficacy in preclinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.65%
Tags
none

FAQ

What is the current stock price of Atossa Therapeutics (ATOS)?

The current stock price of Atossa Therapeutics (ATOS) is $0.6876 as of April 2, 2025.

What is the market cap of Atossa Therapeutics (ATOS)?

The market cap of Atossa Therapeutics (ATOS) is approximately 86.5M.

What is the primary focus of Atossa Therapeutics Inc?

Atossa Therapeutics focuses on developing innovative therapeutics and drug delivery solutions for addressing unmet needs in breast cancer and other breast conditions.

What is (Z)-endoxifen and why is it significant?

(Z)-endoxifen is a potent selective estrogen receptor modulator developed by Atossa Therapeutics. It is significant for its dual action in inhibiting and degrading estrogen receptors, which is crucial for treating certain breast cancers, especially those resistant to standard therapies.

How does Atossa differentiate its drug delivery approach?

Atossa employs innovative intraductal microcatheter technology to deliver therapies directly to the target site. This precision-targeted delivery aims to enhance therapeutic efficacy while minimizing systemic side effects.

What stage is Atossa Therapeutics currently in?

Atossa is a clinical stage biopharmaceutical company with multiple ongoing Phase 2 trials evaluating its key therapeutic candidates, including (Z)-endoxifen.

How does the company strengthen its market position?

The company bolsters its market position through a robust intellectual property portfolio, which includes multiple issued U.S. patents protecting its novel formulations and technologies.

What are the core components of Atossa’s business model?

Atossa’s business model is centered on clinical innovation, targeted drug delivery, strategic collaborations, and leveraging its proprietary therapeutic candidates to address unmet needs in oncology.

Who are the primary beneficiaries of Atossa’s therapies?

The primary beneficiaries are patients, particularly women suffering from breast cancer and related breast conditions, who may not respond effectively to conventional treatments.

How does Atossa’s approach contribute to the field of oncology?

Atossa contributes to oncology by developing advanced therapeutics that combine scientific rigor with innovative drug delivery methods, offering the potential for more effective and tolerable treatment options.
Atossa Therapeutics Inc

Nasdaq:ATOS

ATOS Rankings

ATOS Stock Data

86.45M
129.09M
0.06%
28.55%
7.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE